Category

Archives

Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

Purpose: Patient-derived organoids (PDOs) of lung cancer has been recently introduced, reflecting the genomic landscape of lung cancer. However, clinical relevance of advanced lung adenocarcinoma organoids remains unknown. Here, we examined the ability of PDOs to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.

Experimental design: Eighty-four organoids were established from patients with advanced lung adenocarcinoma. FFPE tumor specimens from corresponding patients were analyzed by whole-exome sequencing (n = 12). Organoids were analyzed by whole-exome sequencing (n = 61) and RNA-sequencing (n = 55). Responses to mono- or combination targeted therapies were examined in organoids and organoid-derived xenografts.

Results: PDOs largely retained somatic alterations including driver mutations of matching patient tumors. PDOs were able to recapitulate progression-free survival and objective responses of NSCLC patients receiving clinically approved tyrosine kinase inhibitors. PDOs recapitulated activity of therapeutic strategies under clinical investigation. YUO-071 harboring an EGFR exon 19 deletion and a BRAF G464A mutation and the matching patient responded to dabrafenib/trametinib combination therapy. YUO-004 and YUO-050 harboring an EGFR L747P mutation was sensitive to afatinib, consistent with the response in the matching patient of YUO-050. Furthermore, we utilized organoids to identify effective therapies for novel molecular targets. We demonstrated efficacy of poziotinib against ERBB2 exon 20 insertions and pralsetinib against RET-fusions.

Conclusions: We demonstrated translational relevance of PDOs in advanced lung adenocarcinoma. PDOs are an important diagnostic tool which can assist clinical decision making and accelerate development of therapeutic strategies.

Related Products

Cat.No. Product Name Information Publications Customer Product Validation
S1166 Cisplatin (NSC 119875) Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared. (455) (5)

Related Targets